July 5, 2026
Sciatilief review When exploring the internet for solutions to chronic nerve pain, many users come across a Sciatilief review that
Tobacco-Free Nicotine Tobacco-Free Nicotine has become a popular choice among adult nicotine users seeking a cleaner and more discreet alternative
的建議劑量是多少 Saxenda 是我們香港醫療中心最受歡迎的減肥藥物之一，許多患者選擇使用它來幫助控制體重並改善整體健康。Saxenda 的主要成分為 liraglutide，屬於胰高血糖素樣肽-1（GLP-1）受體激動劑，最初是用於治療 2 型糖尿病的藥物，但隨著臨床研究的發展，發現它能有效抑制食慾並促進體重減輕，因此被廣泛應用於減肥治療。許多患者在開始使用 Saxenda 之前，最關心的問題之一便是其建議劑量，以確保安全與效果兼顧。 Saxenda 的建議劑量是逐步增加的，以幫助身體適應藥物並減少潛在的副作用，特別是腸胃不適。起始劑量通常為每日 0.6 毫克，並持續至少一週，以讓身體適應 liraglutide 的作用。之後，每週逐步增加劑量，通常的增量為 0.6 毫克，直到達到建議的維持劑量 3.0 毫克。這意味著第二週的劑量為 1.2
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies
Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
The TileDB CEO discusses how the life sciences can overcome these limitations.
James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine
The benefits for brand teams in bolstering their rapid-response capability.
James Foster, CEO and co-founder of Virax Biolabs, discusses how companies can strategize despite hard-to-predict regulatory headwinds.
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial
Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.
Kennedy was confirmed by a mostly party-line vote in the Senate.
Demonstrating clinical benefit is the ultimate gateway to smoother patient access.
The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.
The latest news for pharma industry insiders.
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses where else the the pharmaceutical
Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.
New technology is creating new opportunities but is also causing new complications.
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults
Legos will take over from Roger Dansey, who will begin transitioning to retirement.
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care
Susan Cantrell responds to the tariffs on China, Canada, and Mexico.
In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares and discusses the potential impact
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for refractory
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients
The latest news for pharma industry insiders.
President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.
Senators Durbin and Grassley proposed the new regulations for direct-to-consumer pharma advertising.
2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in
Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours,
Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought to
How pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant
In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and clinical studies and managing chemistry,
The government agency says X no longer suits its communication needs.
Campaign encourages the use of low-dose aspirin to help reduce the risk of preeclampsia and the complications that come with
New partnership hopes to give BSS patients more options for treatment.
As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease,
The latest news for pharma industry insiders.
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken
Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto.
Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of
The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.
This is the latest AI tool from the company to provide insights from public sources.
Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.
The latest news for pharma industry insiders.
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the
Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.
Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder
The latest news for pharma industry insiders.
Casey McPherson, Founder and CEO of Chrysalis Genetics, talks about his daughter’s rare genetic condition, and how it led him
As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to
Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease
Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.
Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease.
The latest news for pharma industry insiders.
The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5%
The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.
John Hood, CEO, Endeavor BioMedicines discusses partnering with advocacy groups to increase awareness of clinical trials for idiopathic pulmonary fibrosis.
The latest news for pharma industry insiders.
Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease
The Swiss company is focused on developing treatments for respiratory conditions, such as asthma and COPD.
The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation.
‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s.
Priority Review was based on results from the Phase III Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis.
San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder
Company leadership urged members and employees to stay safe and follow evacuation orders.
Dan Monahan will serve in the role as the drug goes through Phase III trials.
Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk
Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions.
This acquisition will help generate data from over four million members of MyHealthTeams’ opted-in patient universe.
The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to
Fast Track designation was based on results from a Phase II study, which demonstrated that VGT-309 was safe, well-tolerated, and
While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly
Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.
The partnership will allow CMI to use Anoki’s AI technology to provide targeted advertising.
GlobalData’s new findings show that the Zepbound may become the top WLM in the coming year.
A Q&A with Harvard’s Laura Wegner, serial entrepreneur and Rhodes Scholar-elect.
PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial
Under terms of the deal, Johnson & Johnson will gain an exclusive license to the STAT6 program, with Kaken maintaining
Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York’s
The latest news for pharma industry insiders.
Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients
What can we do to prevent such blatant black eyes to the industry so many of us love?
GLP-1s continue to dominate the market, but can pharma keep up with the demand?
In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), speaks about
Point of care messaging and AI resulted in more targeted campaigns over the past year.
In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on
In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on
Check out our top five most engaged social media posts from the year 2024.
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, shares some specific examples of how
In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on
In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on
New technologies are creating more efficient ways for pharma companies to work directly with consumers.
With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break
The top five episodes of our podcast in the year 2024, highlighted.
John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments.
Pharm Exec covered key players in the industry over the past year.
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that
The latest news for pharma industry insiders.
Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged
Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial.
Approval was based on positive results from the Phase III balance study, where Tryngolza demonstrated a notable placebo-adjusted triglyceride reduction
The molecule is an investigational pre-clinical oral GLP-1 receptor agonist.
The latest news for pharma industry insiders.
In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome.
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of
The technology provides the industry with many opportunities, but it must also navigate a complex regulatory landscape.
These professionals in the healthcare marketing sector have been chosen by their peers for making big moves and taking on
Collaboration aims to enhance PSMA-B ligand, a novel theranostic molecule in development for the treatment of prostate cancer.
Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded
Approval of Steqeyma was based on a comprehensive evidence review, including a Phase III trial in moderate to severe plaque
Breakthrough Therapy designation for Trodelvy was granted based on promising results from the Phase II TROPiCS-03 study, which showed encouraging
The biosimilars market in the US is on the rise, but barriers to greater adoption remain.
Margaret Keegan, the new CEO of Precision Medicine Group, is eager to elevate the profile of the expert-rich service provider
With the Inflation Reduction Act now in flux, how will the government and industry respond?
The Breakthrough Therapy Designation for Jemperli was based on Phase II clinical trial data, showing a 100% clinical complete response
A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and
The regulatory action was supported by results from the Phase III HERCULES trial, which demonstrated a 31% reduction in six-month
Industry voices stress importance of a strategic approach to social media marketing, choosing platforms wisely, prioritize privacy, leveraging targeted advertising
Berger joins Gilead with over 25 years of global drug development experience and will oversee the company’s virology, oncology, and
The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red
Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.
AI provides opportunities to bring people together—not replace them.
Identifying the inflators and deflators, and the role all stakeholders play.
In this Pharmaceutical Executive video interview, Angela Tenuta, President, Full Service Agencies, at EVERSANA INTOUCH, identifies the most significant ethical
Because the AI space is changing rapidly, it’s essential that companies are budgeting correctly and using their investments strategically.
The videos are designed to help bring people together during the holidays.
For pharma manufacturers, the primary requirement for working with high-profile clients is matching their organizational level of urgency and organization.
Breakthrough designation was based on results from the TROPION-Lung05 Phase II trial with support from the TROPION-Lung01 Phase III trial
Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in
In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, discusses how pharmaceutical companies navigate the
In this first part of this roundtable discussion, experts discuss the current perception of AI and how this is impacting
The report gives high rankings to brands from Pfizer and AstraZeneca.
The FDA based the Priority Review designation on results from the Phase III NIAGARA trial, which found that Imfinzi reduced
Mohamed Haitham Ayad, CEO, co-founder, SPIMA Therapeutics, discusses the company’s launch and how multiple institutions have supported its pipeline.
Ziihera’s addition as a category 2A treatment follows the FDA’s accelerated approval of the drug for adults with previously treated,
Approval of Imfinzi was based on results from the ADRIATIC Phase III trial, marking the first systemic immunotherapy available for
Acceptance of the application was based on results from the Phase III STARGLO study, which found that Columvi demonstrated a
The breakthrough designation is based on Phase II clinical trial data, which demonstrated that ATX101 provides sustained pain relief for
Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone
Licensing deals are expected to enhance the oncology, neuroscience, and antibody drug conjugate pipelines of the three manufacturers.
The breakthrough designation is based on data from the expansion cohort of a Phase I/II study evaluating sacituzumab tirumotecan in
Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for
Acceptance of the Biologics License Application of Blenrep was based on promising results from the DREAMM-7 and DREAMM-8 Phase III
The actor is part of a campaign for early colon cancer screening.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
CelloType produces more accurate results when analyzing high content tissue images.
The two companies will work to develop treatments for SBMA.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
Approval was based on the combined results from five studies of adults with supraventricular tachycardia.
Agreement grants Sarepta exclusive rights to several clinical-stage programs for muscular dystrophy, myotonic dystrophy type 1, and more.
Results of the RESILIENT SMA study found that while taldefgrobep demonstrated clinically meaningful motor function improvements in patients with spinal
The proposal aims to reduce out-of-pocket costs for a number of anti-obesity medications by 95%.
Pathway is now the first and only FDA-approved companion diagnostic for identifying HER2-positive biliary tract cancer patients eligible for treatment
2024 Pharmaceutical Executive APEX Award Winners
The drug, developed by UCB, is approved to treat adults with the inflammatory skin disease.
The latest news for pharma industry insiders.
The results say that the industry still lacks talent and skills in this area.
The latest news for pharma industry insiders.
The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya
Dorman previously served as head of Gilead Sciences’ U.S. Oncology Unit.
Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii) provides a chemotherapy-free treatment option for patients with HER2-positive biliary tract cancer, addressing a critical unmet
Ron Lanton, Partner, Lanton Law, ways that the recent FDA PD-1 inhibitor label restrictions could influence future drug development strategies.
Former Chief Oncology Officer and Executive Vice President, Chris Boshoff, MD, PhD, will assume the role and lead all R&D
Syndax describes the drug as the first of its kind.
The news is part of the organization’s goal of demonstrating a commitment to women’s health.
The latest news for pharma industry insiders.
Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for
Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to
Kebillidi is the first gene therapy to gain FDA approval for the treatment of aromatic L-amino acid decarboxylase deficiency.
A look at one biotech’s mission to map the immune system using artificial intelligence—and how its growth as a Big
Developments in the world of artificial intelligence continue to accelerate at a rapid pace. Our November issue of Pharmaceutical Executive
Click the title above for a link to open the Pharmaceutical Executive November 2024 issue in an interactive PDF format.
The resubmission for Dupixent includes new data in pediatric patients with chronic spontaneous urticaria.
Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the
Decisions and strategies related to remote work, AI, and DE&I are especially evolving.
Why tapping the value generated for the next set of therapies is critical.
Approval of Aucatzyl was based on results of the FELIX trial, which demonstrated a 63% overall complete remission rate among
Decision to submit the Biologics License Application of datopotamab deruxtecan was based on feedback from a previously withdrawn application to